[Edaily Reporter NA EUN-KYUNG ] D&D Pharmatech Inc.(347850)’s new drug development strategy—which addresses the entire progression of the disease, from the early stages of macrophage-associated steatohepatitis (MASH) to liver fibrosis and cirrhosis—will be unveiled at the “K-Bio Deal Summit 2026.”

The event will take place at 2:00 p.m. on the 9th of next month at KG Tower in Seodaemun-gu, Seoul, under the theme “K-Bio: Solutions for Global Success Through Innovation.” It has been organized to examine the success strategies of companies leading the global market and to share insights on the growth direction of the domestic bioindustry and investment opportunities. The event is hosted by Edaily and sponsored by the Ministry of Food and Drug Safety, the Korea Pharmaceutical and Bio-Pharma Manufacturers Association, the Korea Bio Association, and KIWOOM Securities.

At D&D Pharmatech Inc., Hong Seong-hoon, Executive Vice President and Chief Financial Officer (CFO), is scheduled to present on the topic “Strategy for Building a Comprehensive MASH New Drug Portfolio.”

MASH is a condition characterized by the accumulation of fat in the liver, accompanied by inflammation, liver cell damage, and fibrosis. While it can lead to cirrhosis and liver cancer, the diverse stages of the disease and comorbidities among patients make it difficult to treat the entire patient population with a single therapeutic agent. Taking these characteristics into account, D&D Pharmatech Inc. maintains a portfolio that encompasses the improvement of metabolic function, reduction of liver fat, and treatment of fibrosis.

“Zabopegduotide” (development code DD01), the cornerstone of the portfolio, reduces fat accumulation in the liver while regulating body weight and blood glucose levels. It is gaining attention as a candidate for global technology transfer after a recent analysis of 48-week tissue biopsy data from a U.S. Phase 2 clinical trial demonstrated the potential for substantial improvement in liver tissue beyond mere weight loss.

For patients whose condition has progressed to cirrhosis, the company is addressing the need with the new anti-fibrotic drug candidate “TLY012.” TLY012 has received approval for its clinical trial protocol from the U.S. Food and Drug Administration (FDA) and aims to enter clinical trials in the second half of this year. This creates a complementary structure where DD01 addresses fatty liver disease, MASH, and early- to moderate-stage fibrosis, while TLY012 expands the treatment scope to include cirrhosis.

D&D Pharmatech Inc. is a biotech company that has demonstrated the capability to translate its new drug portfolio into global business. The company transferred technology—including an obesity treatment candidate utilizing its proprietary peptide oral delivery technology “ORALINK”—to the U.S.-based company Metcera; subsequently, when Pfizer acquired Metcera, D&D Pharmatech Inc.’s technology transfer agreement and related pipeline were also transferred to Pfizer.

This announcement is expected to provide an opportunity to see how D&D Pharmatech Inc.—having clinically validated its technology and secured a global technology transfer—will build a portfolio that spans the entire MASH lifecycle and create new business opportunities.